

For Health Professionals Who Care for People with Cancer

Inside This Issue:

Editor's Choice

New Programs

- **GOCXLACATW** Carboplatin and Paclitaxel for Induction Treatment of Locally Advanced Cervical Cancer
- **GOGCLEU** Leuprolide Acetate for Advanced Granulosa Cell Carcinoma
- **ULYOGGEMOX** Obinutuzumab, Glofitamab, Gemcitabine and Oxaliplatin for Treatment of Lymphoma

Drug Update

Pegfilgrastim

Cancer Drug Manual®

New pegfilgrastim, mirvetuximab soravtansine

Revised alemtuzumab, azacitidine, cyclophosphamide, filgrastim, glofitamab, tocilizumab

Chemotherapy Preparation and Stability Chart alemtuzumab

IV Bag Size & Vial Selection mesna

Continuing Education

FPON Webinar Adolescents and Young Adults with Cancer

ST Update Editorial Board

Board Changes

Benefit Drug List

New GOCXLACATW, GOGCLEU, ULYOGGEMOX, inpatient only: pegfilgrastim

Protocols, PPPOs and Patient Handouts

New **GO** GOCXLACATW, GOGCLEU **LY** ULYOGGEMOX

Revised **BR** BRAJAC, BRAJACT, BRAJACTG, BRAJACTT, BRAJACTTG, BRAJDAC, BRAJDC, BRAJDCARBT, BRAJFEC, BRAJFECD, BRAJFECDT, BRAJPN, BRAJPNCT, BRAJPNT, BRAJTDC, BRAVABR, UBRAVCAFLV, BRAVPBFLV, BRAVPPN, BRAVPTRAD, BRAVSG, BRLAACD, BRLAACDT, BRLACPNAC, BRLACPNACG, BRLAPNAC, BRLAPNACG, BRLATACG **CN** UCNTTF **GI** GIAAVCT, GIPGEMABR **GO** GOCABR, GOCABRBEV, GOCXCPNBP, GOCXCPNP, GOEAVDPNC, GOEAVPPNC, GOENDAJCAT, GOEP, GOOVCATM, GOOVCATR, GOOVCATX, GOOVDOC, GOOVTAX3, GOOVTOP **GU** GUEP, GUOTTIP, GUPAZO, UGUPLVT **LK** ULKAMLAVEN **LY** ULYEPCOR, ULYOGLOFIT, LYPOLARCHP **SA** SAAVIME3, SAAVTC, SANAHDMAP **SC** SCCRS

Resources and Contact Information

Editor's Choice

New Programs

BC Cancer Provincial Systemic Therapy has approved the following new treatment programs effective 01 June 2026. Full details of all treatment programs are available in the [Chemotherapy Protocols](#) section of the BC Cancer website.

Gynecologic Oncology

Carboplatin and Paclitaxel as Induction Treatment of Locally Advanced Cervical Cancer (GOCXLACATW) –

The BC Cancer Gynecologic Oncology Tumour Group is implementing induction chemotherapy with carboplatin-paclitaxel in patients with locally advanced cervical cancer who will be receiving subsequent cisplatin chemoradiation (GOCXCRT). The goal of weekly induction chemotherapy is to reduce tumour volume and micrometastatic disease prior to definitive chemoradiation.

The randomised phase III INTERLACE trial of induction carboplatin-paclitaxel chemotherapy followed by cisplatin-based chemoradiation vs. standard of care (chemoradiation alone) improved 5-year overall survival (OS) and progression-free survival (PFS) in patients with locally advanced cervical cancer.¹ The

Editor's Choice

median interval between the end of induction chemotherapy and initiating chemoradiation was 7 days. Grade 3 or greater adverse events were reported in 59% of patients in the induction chemotherapy group versus 48% of patients in the standard of care group.

Leuprolide Acetate for Advanced Granulosa Cell Carcinoma (GOGCLEU) – The BC Cancer Gynecologic Oncology Tumour Group is implementing treatment with leuprolide acetate, a luteinizing hormone releasing hormone (LHRH) agonist, for patients with metastatic granulosa cell carcinoma of the ovary that is no longer amenable to surgical resection. Patients must have received at least one prior line of therapy (chemotherapy or endocrine therapy). In a large cohort study of patients with recurrent granulosa cell tumours, treatment with leuprolide acetate was comparable to chemotherapy in terms of PFS, supporting its use for relapsed granulosa cell tumours.²

Lymphoma

Obinutuzumab, Glofitamab, Gemcitabine and Oxaliplatin for Treatment of Lymphoma (ULYOGGEMOX) – The BC Cancer Lymphoma Tumour Group is introducing glofitamab in combination with gemcitabine-oxaliplatin (GemOx) chemotherapy for transplant-ineligible relapsed/refractory lymphomas including diffuse large B-cell lymphoma (DLBCL). To mitigate the risk of cytokine release syndrome (CRS), a single obinutuzumab dose is used in the first cycle. Refer to treatment protocol for full eligibility criteria. BC Cancer Compassionate Access Program (CAP) approval is required.

In the randomised, open-label phase III STARGLO trial, glofitamab with GemOx chemotherapy demonstrated a significant OS benefit compared with rituximab-GemOx in patients with transplant-ineligible DLBCL and one or more previous lines of therapy.^{3,4} A single obinutuzumab dose was used in glofitamab-exposed patients; CRS occurred in almost half these patients but was predominantly low grade.

References:

1. McCormack M, Eminowicz G, Gallardo D, et al. Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial. *Lancet* 2024;404:1525-1535. [https://doi.org/10.1016/S0140-6736\(24\)01438-7](https://doi.org/10.1016/S0140-6736(24)01438-7)
2. Foster KI, Flores Legarreta A, Kamat R, et al. Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors. *Am J Obstet Gynecol* 2023;228(6):724.e1–724.e9. <https://doi.org/10.1016/j.ajog.2023.02.029>
3. Abramson JS, Ku M, Hertzberg M, et al. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open label trial. *Lancet* 2024;404:1940-1954. [https://doi.org/10.1016/S0140-6736\(24\)01774-4](https://doi.org/10.1016/S0140-6736(24)01774-4)
4. Canada's Drug Agency (CDA-AMC). Reimbursement Recommendation. Glofitamab (Columvi®). *Canadian Journal of Health Technologies* 2025;5(10):1-26. <https://doi.org/10.51731/cjht.2025.1256>

Drug Update

Pegfilgrastim

Effective 01 June 2026, BC Cancer is introducing pegfilgrastim, a pegylated form of filgrastim, for outpatient use. This aligns with BC PharmaCare's implementation of Special Authority coverage for the pegfilgrastim biosimilars LAPELGA, FULPHILA and ZIEXTENZO.

Filgrastim and Pegfilgrastim in BC Cancer Protocols

Until now, BC Cancer has used filgrastim as the sole granulocyte-colony-stimulating factor (G-CSF) option across systemic therapy protocols for the primary or secondary prophylaxis of febrile neutropenia (FN).

Primary prophylaxis uses G-CSF to prevent neutropenic complications, decrease the incidence of FN and hospitalization, and maintain dose-density in curative-intent regimens when the risk of FN is greater than 20%.¹⁻⁴ Secondary prophylaxis uses G-CSF in subsequent chemotherapy cycles following a prior FN episode. Pegfilgrastim is being added as an alternative G-CSF for primary and secondary prophylaxis in eligible protocols.

Pegfilgrastim Dosing and Administration

Pegfilgrastim is administered as a single 6 mg subcutaneous dose, once per chemotherapy cycle. BC Cancer will be using the pegfilgrastim biosimilar (LAPELGA) 6 mg pre-filled syringe. Pegfilgrastim must be administered no sooner than 24 hours after cytotoxic chemotherapy. The Health Canada-approved pegfilgrastim product monograph states pegfilgrastim should be administered at least 14 days before the next chemotherapy dose.⁵ Guidelines, supported by clinical trial and retrospective data, however, suggest that a minimum 12-day interval is reasonable, enabling use in dose-dense regimens.^{4,6}

Comparison of Pegfilgrastim with Filgrastim

Multiple randomized trials and meta-analyses demonstrate that pegfilgrastim has comparable efficacy to filgrastim, with improved convenience and adherence.^{1,2} As a pegylated form of filgrastim, pegfilgrastim has prolonged persistence in the body which allows for administration once per chemotherapy cycle. Due to its prolonged activity, however, the timeframe for administering pegfilgrastim is more restrictive than for filgrastim. By comparison, filgrastim has a shorter duration of effect and is available in two strengths. Because filgrastim allows for finer titration of dose and duration, it remains the preferred G-CSF for treatment/rescue of prolonged FN following chemotherapy.

Treatment Protocol Updates

Pegfilgrastim has been incorporated into filgrastim-containing BC Cancer treatment protocols that allow pegfilgrastim to be administered at least 24 hours after chemotherapy AND administered at least 12 days before the next scheduled cycle. Where appropriate, start dates for filgrastim have been revised to align with pegfilgrastim. Refer to the protocol by which the patient is being treated for details on pegfilgrastim administration. The *Revised Protocols, PPPOs and Patient Handouts* table at the end of this issue highlights updated protocols; work is ongoing to implement pegfilgrastim across tumour groups. The BC PharmaCare Special Authority request form for biosimilar pegfilgrastim is available in the [Reimbursement and Forms](#) section of the BC Cancer website or directly through [BC PharmaCare](#).

References:

1. UpToDate. Larson RA. Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation. Yushak, M (editor). Updated March 27, 2026; accessed May 26, 2026. Available at: www.uptodate.com
2. Gyawali B, Bohlke K, Dickter JK, et al. WBC growth factors: ASCO guideline update. *J Clin Oncol* 2026;44(9):812-824. <https://doi.org/10.1200/JCO-25-02938>
3. Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. *Ann Oncol* 2016;27(Suppl 5):111-118. <https://doi.org/10.1093/annonc/mdw325>
4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: hematopoietic growth factors. V.3.2026. Accessed April 21, 2026. Available at: <https://www.nccn.org>
5. Amgen Canada Inc. NEULASTA product monograph. Mississauga, Ontario; January 8, 2021.
6. Crespo A, Forbes L, Vu K, et al. Prevention and outpatient management of febrile neutropenia in adult cancer patients: clinical practice guideline. Cancer Care Ontario. Updated January 2022; accessed May 26, 2026. Available at: <https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/38561>

All documents are available in the [Cancer Drug Manual[©]](#) on the BC Cancer website.

New Documents

Note that the following drug is not a BC Cancer Benefit Drug when used as supportive care in the outpatient setting. The corresponding Monograph and Patient Handout are made available for reference only.

The **Pegfilgrastim Monograph** and **Patient Handout** have been developed with expert review provided by Dr. Natalie Levasseur (medical oncologist, BC Cancer Breast Tumour Group), Michelle Lafreniere (nurse representative, BC Cancer Professional Practice Nursing) and Orysa Fetterly (tumour group pharmacist representative, BC Cancer Provincial Pharmacy). Pegfilgrastim is composed of filgrastim (a granulocyte-colony-stimulating factor, G-CSF) covalently bonded to polyethylene glycol (PEG). It is a long-acting form of filgrastim and is also known as pegylated G-CSF. Pegfilgrastim accelerates neutrophil recovery and is used in patients receiving cytotoxic chemotherapy to prevent febrile neutropenia and reduce infection risk. The usual dose is a single 6 mg subcutaneous injection once per chemotherapy cycle.

Highlights from these documents include:

- pegfilgrastim stimulates the rapid proliferation of myeloid cells; these cells may be sensitive to cytotoxic chemotherapy, therefore pegfilgrastim should not be administered in the period of 12 days **before** through 24 hours **after** the administration of cytotoxic chemotherapy
- mild to moderate **bone pain** has been reported and is usually managed with non-narcotic analgesics

Pegfilgrastim has been evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

The **Mirvetuximab Soravtansine Interim Monograph** has been expanded to a full **Monograph**, and a **Patient Handout** has been developed. Expert review was provided by Dr. Yvette Drew (medical oncologist, BC Cancer Gynecologic Oncology Tumour Group) and Jelena Mucovic (tumour group pharmacist representative, BC Cancer Provincial Pharmacy). All monograph sections have been reviewed and updated. The following sections have been added or expanded: *Mechanism of Action, Pharmacokinetics, Special Precautions, Side Effects, Interactions, Solution Preparation and Compatibility* and *Dosage Guidelines*. Mirvetuximab soravtansine is an antibody-drug conjugate (ADC) composed of a chimeric IgG anti-FR α monoclonal antibody linked to a maytansoid antitubulin agent (DM4) via a cleavable linker. Mirvetuximab soravtansine is used as monotherapy in the treatment of FR α -positive ovarian cancer. The usual dose is 6 mg/kg (using an adjusted ideal body weight) given IV once every three weeks.

Highlights from these documents include:

- **ocular adverse events** are common, including corneal events; lubricating eye drops are recommended throughout treatment, but steroid eye drops may also be required for the management of keratopathy
- **peripheral neuropathies** are reported in approximately one-third of patients
- antiemetics and premedication with corticosteroid, antihistamine, and antipyretics are recommended with each infusion

Revised Documents

Alemtuzumab Monograph

Supply and Storage: updated with current Canadian brand (sanofi-aventis); deleted Genzyme brand

Azacitidine Monograph

Pharmacokinetics: updated with oral (tablet) formulation data

Cyclophosphamide Monograph

Mechanism: updated to include information related to activation

Special Precautions: created *Cautions* section (moved heart disease and immunogenicity from other sections; new information about PAP test); updated *Carcinogenicity, Mutagenicity, Fertility, Pregnancy* and *Breastfeeding* sections; deleted FDA pregnancy category

Side Effects table/paragraphs:

- removed extra details from nasal congestion, cardiovascular, SIADH and hemorrhagic cystitis sections in table and moved to paragraphs; added “see paragraph” statements
- updated paragraph for cardiac toxicity (mostly edited for clarity; rearranged content)
- minor edits to paragraphs for hemorrhagic cystitis for clarity
- deleted paragraph for immunogenicity (see note in Cautions above)
- replaced hyperuricemia paragraph with current template version
- updated nasal stuffiness and pulmonary toxicity paragraphs
- minor edits to SIADH paragraph

Drug Interactions table: deleted interactions that are not pharmacokinetic interactions as well as interactions that are not included in Lexicomp or Micromedex; separated phenobarbital and rifampin from phenytoin line and updated the management column

Supply and Storage: updated with current Canadian brands (Baxter: deleted 200 mg vial and 25 mg tablet)

Parenteral Administration table: removed IV infusion volume (for intermittent infusion)

Dosage Guidelines: changed rounding recommendation to 50 mg (as 25 mg tablet discontinued); updated dosing in hepatic failure to include information related to bioactivation

Filgrastim Patient Handout

Storage bullet: added information to remove from fridge and allow to come to room temperature prior to injection

Side Effects table: updated *bone pain* bullet

Check with Healthcare Team bullet: added abdominal pain

Glofitamab Monograph

Dosage Guidelines: added new BC Cancer protocol (ULYOGGEMOX)

Tocilizumab Interim Monograph

Supply and Storage: updated with new biosimilar (Celltrion)

Chemotherapy Preparation and Stability Chart

Alemtuzumab

Updated to sanofi-aventis brand; deleted Genzyme brand

IV Bag Size & Vial Selection

Mesna has been updated on the [IV Bag Size & Vial Selection](#) table.

Continuing Education

Family Practice Oncology Network | Adolescents and Young Adults with Cancer

The Family Practice Oncology Network (FPON) is pleased to announce a webinar with Dr. Cheryl Heykoop, Dr. Alannah Smrke and Dr. Kristin Marr on **Adolescents and Young Adults with Cancer: Unique Needs and Practical Resources**. The webinar is Thursday 18 June 2026, from 0800-0900h, as part of the accredited, complimentary FPON webcasts.

By the end of the session, participants will be able to:

- Describe the unique clinical and support needs of adolescents and young adults (AYAs) with cancer amid increasing incidence.
- Integrate AYA-focused resources, including fertility care and specialized counselling, into practice.
- Review plans for a provincial AYA care and support program, including navigation, peer and virtual support, and survivorship care.

For more information and link to registration, visit:

[FPON Webinar | Adolescents and Young Adults with Cancer | UBC CPD](#)

ST Update Editorial Board

Board Changes

The Systemic Therapy Update Editorial Board would like to thank Jeevan Dosanjh for her commitment and contributions, as she steps down from the board to fulfill other priorities within her nurse educator role. We are pleased to welcome Michelle Lafreniere to the ST Update Editorial Board!

Benefit Drug List

New Programs

The following treatment programs have been added to the BC Cancer [Benefit Drug List](#) effective 01 June 2026:

Protocol Title	Protocol Code	Benefit Status
Induction Treatment of Locally Advanced Cervical Cancer using Carboplatin and Paclitaxel	GOCXLACATW	Class I
Treatment of Advanced Granulosa Cell Carcinoma using Leuprolide Acetate	GOGCLEU	Class I
Treatment of Lymphoma using Obinutuzumab , Glofitamab , Gemcitabine and Oxaliplatin	ULYOGGEMOX	Restricted
Pegfilgrastim (LAPELGA, FULPHILA, ZIEXTENZO) : reimbursed for inpatient administration only – see BC PharmaCare Special Authority Form for eligible indications	---	Inpatient only

Highlights of New & Revised Protocols, PPPOs and Patient Handouts

BC Cancer Treatment Protocols, Provincial Preprinted Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program (CAP) approval are prefixed with the letter **U**.

NEW Protocols, PPPOs and Patient Handouts (*new documents checked*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GOCXLACATW	Induction Treatment of Locally Advanced Cervical Cancer using Carboplatin and Paclitaxel	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
GOGCLEU	Treatment of Advanced Granulosa Cell Carcinoma using Leuprolide Acetate	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
ULYOGGEMOX	Treatment of Lymphoma using Obinutuzumab, Glofitamab, Gemcitabine and Oxaliplatin	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> 3 x PPPOs	<input type="checkbox"/>

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BR Breast				
BRAJAC	Adjuvant Therapy for Breast Cancer using Doxorubicin and Cyclophosphamide	<i>Pegfilgrastim option added; contact information updated; units of measure clarified</i>	<i>Pegfilgrastim option added; units of measure clarified</i>	---
BRAJACT	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Doxorubicin and Cyclophosphamide Followed by Paclitaxel	<i>Pegfilgrastim option added; contact information updated; units of measure clarified</i>	<i>Pegfilgrastim option added; units of measure clarified</i>	---
BRAJACTG	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Dose Dense Therapy: Doxorubicin and Cyclophosphamide Followed by Paclitaxel	<i>Pegfilgrastim option added; contact information and filgrastim treatment updated; eligibility, exclusions and units of measure clarified</i>	<i>Pegfilgrastim option added; units of measure clarified</i>	<i>Pegfilgrastim option added; side effects clarified</i>
BRAJACTT	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Doxorubicin and Cyclophosphamide Followed by Paclitaxel and Trastuzumab	<i>Pegfilgrastim option added</i>	<i>Pegfilgrastim option added</i>	---
BRAJACTTG	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Dose Dense Therapy: Doxorubicin and Cyclophosphamide Followed by Paclitaxel and Trastuzumab	<i>Pegfilgrastim option added; filgrastim treatment updated</i>	<i>Pegfilgrastim option added; tests clarified</i>	<i>Pegfilgrastim option added; side effects clarified</i>

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BRAJDAC	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Cyclophosphamide, Doxorubicin and Docetaxel	<i>Pegfilgrastim option added; contact information updated; units of measure clarified</i>	<i>Pegfilgrastim option added; units of measure clarified</i>	<i>Pegfilgrastim option added; side effects clarified</i>
BRAJDC	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Docetaxel and Cyclophosphamide	<i>Pegfilgrastim option added; contact information updated; units of measure clarified</i>	<i>Pegfilgrastim option added; units of measure clarified</i>	<i>Pegfilgrastim option added; side effects clarified</i>
BRAJDCARBT	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Docetaxel, Carboplatin and Trastuzumab	<i>Pegfilgrastim option added</i>	<i>Pegfilgrastim option added</i>	<i>Pegfilgrastim option added; side effects clarified</i>
BRAJFEC	Adjuvant Therapy for Breast Cancer using Fluorouracil, Epirubicin and Cyclophosphamide	<i>Pegfilgrastim option added; tests and units of measure clarified; contact information updated</i>	<i>Pegfilgrastim option added; tests and units of measure clarified</i>	<i>G-CSF options added; side effects clarified</i>
BRAJFECD	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Fluorouracil, Epirubicin, Cyclophosphamide and Docetaxel	<i>Pegfilgrastim option added; contact information updated; units of measure clarified</i>	<i>Pegfilgrastim option added; units of measure clarified</i>	---
BRAJFECDT	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Fluorouracil, Epirubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab	<i>Pegfilgrastim option added</i>	<i>Pegfilgrastim option added</i>	---
BRAJPN	Alternative Adjuvant Therapy for Breast Cancer using Paclitaxel NAB	<i>Neuropathy dose modifications table clarified</i>	---	---
BRAJPNCT	Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using Paclitaxel NAB, Carboplatin and Trastuzumab	<i>Pegfilgrastim option added; neuropathy dose modifications table and tests clarified</i>	<i>Pegfilgrastim option added</i>	---
BRAJPNT	Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using Paclitaxel NAB and Trastuzumab	<i>Neuropathy dose modifications table clarified</i>	---	---
BRAJTDC	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Trastuzumab, Docetaxel and Cyclophosphamide	<i>Pegfilgrastim option added; contact information updated</i>	<i>Pegfilgrastim option added</i>	---
BRAVABR	Palliative Therapy for Metastatic Breast Cancer using Paclitaxel NAB	<i>Neuropathy dose modifications table clarified</i>	---	---
UBRAVCAFLV	Therapy of Advanced Breast Cancer using Capivasertib and Fulvestrant with or without LHRH Agonist	<i>Treatment clarified; contact information updated</i>	<i>Dosing interval clarified</i>	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BRAVPBFLV	Therapy of Advanced Breast Cancer using Palbociclib and Fulvestrant with or without LHRH Agonist	<i>Treatment and dose modifications tables clarified; contact information updated</i>	<i>Treatment interval updated</i>	---
BRAVPPN	Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab and Paclitaxel NAB	<i>Neuropathy dose modifications table clarified</i>	---	---
BRAVPTRAD	Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab, and Docetaxel as First-Line Treatment for Advanced Breast Cancer	<i>Pegfilgrastim option added; tests and units of measure clarified; contact information updated</i>	---	---
BRAVSG	Palliative Therapy for Metastatic Breast Cancer using Sacituzumab Govitecan	<i>Pegfilgrastim option added; tests and units of measure clarified</i>	<i>Pegfilgrastim option added; tests and units of measure clarified</i>	---
BRLAACD	Treatment of Locally Advanced Breast Cancer using Doxorubicin and Cyclophosphamide Followed by Docetaxel	<i>Pegfilgrastim option added; contact information updated; eligibility, exclusions and units of measure clarified</i>	<i>Pegfilgrastim option added; units of measure clarified</i>	<i>Pegfilgrastim option added; side effects and title clarified</i>
BRLAACDT	Treatment of Locally Advanced Breast Cancer using Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab	<i>Pegfilgrastim option added</i>	<i>Pegfilgrastim option added</i>	<i>G-CSF options added; title and side effects clarified</i>
BRLACPNAC	Alternative Neoadjuvant Therapy for Triple Negative Breast Cancer using Carboplatin and Paclitaxel NAB Followed by Doxorubicin and Cyclophosphamide	<i>Pegfilgrastim option added; neuropathy dose modifications table clarified</i>	<i>Pegfilgrastim option added; tests clarified</i>	---
BRLACPNACG	Alternative Neoadjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: Carboplatin and Paclitaxel NAB Followed by Doxorubicin and Cyclophosphamide	<i>Pegfilgrastim option added; filgrastim treatment updated; neuropathy dose modifications table clarified</i>	<i>Pegfilgrastim option added; tests clarified</i>	<i>Pegfilgrastim option added; side effects clarified</i>
BRLAPNAC	Alternative Neoadjuvant Therapy for Locally Advanced Breast Cancer using Paclitaxel NAB Followed by Doxorubicin and Cyclophosphamide	<i>Pegfilgrastim option added; neuropathy dose modifications table clarified</i>	<i>Pegfilgrastim option added; tests clarified</i>	---
BRLAPNACG	Alternative Neoadjuvant Therapy for Breast Cancer using Dose Dense Therapy: Paclitaxel NAB Followed by Doxorubicin and Cyclophosphamide	<i>Pegfilgrastim option added; filgrastim treatment updated; neuropathy dose modifications table clarified</i>	<i>Pegfilgrastim option added</i>	<i>Pegfilgrastim option added; side effects clarified</i>

REVISED Protocols, PPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPO	Handout
BRLATACG	Neoadjuvant Therapy for Breast Cancer using Dose Dense Therapy: Paclitaxel Followed by Doxorubicin and Cyclophosphamide	<i>Pegfilgrastim option added; contact information and filgrastim treatment updated; units of measure clarified</i>	<i>Pegfilgrastim option added; tests and units of measure clarified</i>	---
CN Neuro-Oncology				
UCNTTF	Therapy of Glioblastoma using Tumour Treating Fields (OPTUNE GIO)	---	---	<i>Removed MR images instructions</i>
GI Gastrointestinal				
GIAAVCT	First-Line Palliative Treatment of Metastatic Anal Squamous Cell Carcinoma using Carboplatin and Weekly Paclitaxel	---	---	<i>Updated</i>
GIPGEMABR	First Line Treatment of Locally Advanced and Metastatic Pancreatic Cancer with Paclitaxel NAB and Gemcitabine	<i>Neuropathy dose modifications table clarified</i>	---	---
GO Gynecologic Oncology				
GOCABR	Alternative Treatment of Gynecological Malignancies using Carboplatin and Paclitaxel NAB	<i>Pegfilgrastim option added; neuropathy dose modifications table clarified</i>	---	---
GOCABRBEV	Alternative Treatment of Gynecological Malignancies using Bevacizumab, Carboplatin and Paclitaxel NAB	<i>Pegfilgrastim option added; neuropathy dose modifications table clarified</i>	---	---
GOCXCPNBP	Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Bevacizumab, Carboplatin, Paclitaxel NAB and Pembrolizumab	<i>Neuropathy dose modifications table clarified</i>	---	---
GOCXCPNP	Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Carboplatin, Paclitaxel NAB and Pembrolizumab	<i>Neuropathy dose modifications table clarified</i>	---	---
GOEAVDPNC	Alternative Treatment of Endometrial Cancer using Dostarlimab with Paclitaxel NAB and Carboplatin	<i>Neuropathy dose modifications table clarified</i>	---	---
GOEAVPPNC	Alternative Treatment of Advanced or Recurrent Endometrial Cancer using Pembrolizumab, Paclitaxel NAB and Carboplatin	<i>Neuropathy dose modifications table clarified</i>	---	---
GOENDAJCAT	Neoadjuvant or Adjuvant Treatment of Endometrial Cancer using Carboplatin and Paclitaxel	<i>Pegfilgrastim option added</i>	---	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GOEP	Therapy of Dysgerminomatous Ovarian Germ Cell Cancer using Cisplatin and Etoposide	<i>Pegfilgrastim option added</i>	<i>Pegfilgrastim option added</i>	---
GOOVCATM	Primary Treatment of No Visible Residual (Moderate-High Risk) Invasive Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer using Carboplatin and Paclitaxel	<i>Pegfilgrastim option added; eligibility and exclusions clarified</i>	---	---
GOOVCATR	Second Line Treatment of Invasive Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer Relapsing after Primary Treatment using Paclitaxel and Carboplatin	<i>Pegfilgrastim option added; eligibility and exclusions clarified</i>	---	---
GOOVCATX	Primary Treatment of Visible Residual (Extreme Risk) Invasive Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer using Carboplatin and Paclitaxel	<i>Pegfilgrastim option added; eligibility and exclusions clarified</i>	---	---
GOOVDOC	Treatment of Relapsed/Progressing Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma using Docetaxel	<i>Pegfilgrastim option added; eligibility and units of measure clarified</i>	---	---
GOOVTAX3	Treatment of Relapsed/Progressing Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma using Paclitaxel	<i>Pegfilgrastim option added; eligibility clarified</i>	---	---
GOOVTOP	Treatment of Relapsed/Progressing Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma using Topotecan	<i>Pegfilgrastim option added; eligibility and exclusions clarified</i>	---	---
GU Genitourinary				
GUPEP	Etoposide-Cisplatin Protocol for Germ Cell Cancers	<i>Pegfilgrastim option added; contact information updated</i>	<i>Pegfilgrastim option added</i>	---
GUOTTIP	Neoadjuvant Therapy for Penile Squamous Cell Carcinoma using Paclitaxel, Ifosfamide and Cisplatin (TIP)	<i>Pegfilgrastim option added; units of measure clarified</i>	Inpatient PPPO <i>Pegfilgrastim option added</i>	<i>Pegfilgrastim option added</i>
GUPAZO	Palliative Therapy for Renal Cell Carcinoma using Pazopanib	<i>Duration of treatment added</i>	---	---
UGUPLVT	Treatment of Metastatic Castration Resistant Prostate Cancer using Lutetium (¹⁷⁷ Lu) Vipivotide Tetraxetan (PLUVICTO)	<i>Dose modifications updated</i>	---	---
LK Leukemia and BMT				
ULKAMLAVEN	Therapy of Acute Myeloid Leukemia using Azacitidine and Venetoclax	<i>Tests updated; dose modifications clarified</i>	---	---
LY Lymphoma				
ULYPCOR	Treatment of Lymphoma using Epcoritamab	<i>Eligibility and supportive care medications updated</i>	Cycle 1 PPPO <i>Monitoring updated</i>	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
ULYOGLOFIT	Treatment of Lymphoma using Obinutuzumab and Glofitamab	<i>Treatment planning table removed; eligibility and treatment updated</i>	Cycle 1 & Cycles 2-12 PPPOs <i>Monitoring updated</i>	---
LYPOLARCHP	Treatment of Lymphoma with Doxorubicin, Cyclophosphamide, Prednisone, Rituximab and Polatuzumab Vedotin	<i>Eligibility updated; appendix added</i>	---	---
SA Sarcoma				
SAAVIME3	3-Day Etoposide and Ifosfamide-Mesna for Patients with Advanced Soft Tissue or Bony Sarcomas	<i>Pegfilgrastim option added; contact information, dose modifications and precautions updated; eligibility, tests and units of measure clarified</i>	---	---
SAAVTC	Treatment of Recurrent and Refractory Neuroblastoma, Ewing's Sarcoma, Osteogenic Sarcoma or Rhabdomyosarcoma with Topotecan and Cyclophosphamide	<i>Pegfilgrastim option added; eligibility, tests and units of measure clarified; contact information updated</i>	<i>Pegfilgrastim option added; tests and units of measure clarified</i>	---
SANAHDMAP	Neoadjuvant and Adjuvant Therapy for Osteosarcoma using High-Dose Methotrexate, Doxorubicin and Cisplatin	<i>Pegfilgrastim option added; urine alkalization clarified; contact information updated</i>	Cycles 1 to 4, Week 1 Inpatient PPPO <i>Pegfilgrastim option added; units of measure clarified</i> Methotrexate Inpatient PPPO <i>Urine alkalization and units of measure clarified</i>	---
SC Supportive Care				
SCCRS	Cytokine Release Syndrome Management	<i>Management updated</i>	---	---

Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update		
Systemic Therapy Update Editor	604-877-6000 x 672649	bulletin@bccancer.bc.ca
Oncology Drug Information Cancer Drug Manual Editor	604-877-6275	druginfo@bccancer.bc.ca
Pharmacy Oncology Certification	250-712-3900 x 686820	rxchemocert@bccancer.bc.ca
CAP – Compassionate Access Program	604-877-6277	cap_bcca@bccancer.bc.ca fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	oscar@bccancer.bc.ca fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 requests@bccancer.bc.ca
Library Document Delivery	604-675-8002	requests@bccancer.bc.ca
Pharmacy Professional Practice Professional Practice, Nursing Provincial Systemic Therapy Network	604-877-6000 x 672247 604-877-6000 x 672623 604-877-6000 x 672247	mclin@bccancer.bc.ca BCCancerPPNAdmin@phsa.ca ProvincialSystemicOffice@bccancer.bc.ca
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: bulletin@bccancer.bc.ca		

Editorial Review Board

Anne Dar Santos, BScPharm, PharmD (Editor)
Jelena Mucovic, BScPharm (Assistant Editor)
Mário de Lemos, PharmD, MSc(Oncol)
Alina Gerrie, MD, MPH, FRCPC

Yuna Jang, RN
Michelle Lafreniere, BScN, RN
Alison Pow, BScPharm